  Throughout the different phases of a drug development program, randomized
trials are used to establish the tolerability, safety, and efficacy of a
candidate drug. At each stage one aims to optimize the design of future studies
by extrapolation from the available evidence at the time. This includes
collected trial data and relevant external data. However, relevant external
data are typically available as averages only, for example from trials on
alternative treatments reported in the literature. Here we report on such an
example from a drug development for wet age-related macular degeneration. This
disease is the leading cause of severe vision loss in the elderly. While
current treatment options are efficacious, they are also a substantial burden
for the patient. Hence, new treatments are under development which need to be
compared against existing treatments. The general statistical problem this
leads to is meta-analysis, which addresses the question of how we can combine
datasets collected under different conditions. Bayesian methods have long been
used to achieve partial pooling. Here we consider the challenge when the model
of interest is complex (hierarchical and nonlinear) and one dataset is given as
raw data while the second dataset is given as averages only. In such a
situation, common meta-analytic methods can only be applied when the model is
sufficiently simple for analytic approaches. When the model is too complex, for
example nonlinear, an analytic approach is not possible. We provide a Bayesian
solution by using simulation to approximately reconstruct the likelihood of the
external summary and allowing the parameters in the model to vary under the
different conditions. We first evaluate our approach using fake-data
simulations and then report results for the drug development program that
motivated this research.
